A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel | Zendy

YiLong Wu | Zendy; Chang-Li Wang | Zendy; MeiLin Liao | Zendy; Zhong-Zhen Guan | Zendy; Chen-Yan Gao | Zendy; Shun Lü | Zendy; Ming-Fang Zhao | Zendy; Jie Wang | Zendy; Xiaoqing Liu | Zendy; Jin-Ji Yang | Zendy; Jun Liang | Zendy; Wei-Min Mao | Zendy; Baohui Han | Zendy; XuChao Zhang | Zendy; Yong Song | Zendy; Ji-Feng Feng | Zendy; Sheng-Lin Ma | Zendy; Gang Wu | Zendy; Cai-Cun Zhou | Zendy; KeNeng Chen | Zendy; Ying Cheng | Zendy; Yong He | Zendy; Chun Chen | Zendy; Qun Wang | Zendy; Ji-Zhen Lin | Zendy; Bo Zhu | Zendy; Yunpeng Liu | Zendy; Yi Hu | Zendy; Guibin Qiao | Zendy; Qing Zhou | Zendy; Qi-Bin Song | Zendy; Nan Wu | Zendy; Lin Wu | Zendy; Cheng Huang | Zendy; Xiaolong Fu | Zendy; Jianping Xiong | Zendy; Jie Hu | Zendy; Cheng-Ping Hu | Zendy; Jian-Hua Chang | Zendy; Qiong Zhao | Zendy; Jun Zhao | Zendy; Peng-Hui Zhou | Zendy; Zhi-Yong Ma | Zendy; YuAn Chen | Zendy; Helong Zhang | Zendy; Fan Yang | Zendy; Jianjun Wang | Zendy; Yue-Yin Pan | Zendy; Xue-Ning Yang | Zendy; Yun Fan | Zendy; Zhe Liu | Zendy; Wen Fan | Zendy; g Yang | Zendy; Yan-Fang Guan | Zendy; Hao Sun | Zendy; WenZhao Zhong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel

Author(s) -

YiLong Wu,

Chang-Li Wang,

MeiLin Liao,

Zhong-Zhen Guan,

Chen-Yan Gao,

Shun Lü,

Ming-Fang Zhao,

Jie Wang,

Xiaoqing Liu,

Jin-Ji Yang,

Jun Liang,

Wei-Min Mao,

Baohui Han,

XuChao Zhang,

Yong Song,

Ji-Feng Feng,

Sheng-Lin Ma,

Gang Wu,

Cai-Cun Zhou,

KeNeng Chen,

Ying Cheng,

Yong He,

Chun Chen,

Qun Wang,

Ji-Zhen Lin,

Bo Zhu,

Yunpeng Liu,

Yi Hu,

Guibin Qiao,

Qing Zhou,

Qi-Bin Song,

Nan Wu,

Lin Wu,

Cheng Huang,

Xiaolong Fu,

Jianping Xiong,

Jie Hu,

Cheng-Ping Hu,

Jian-Hua Chang,

Qiong Zhao,

Jun Zhao,

Peng-Hui Zhou,

Zhi-Yong Ma,

YuAn Chen,

Helong Zhang,

Fan Yang,

Jianjun Wang,

Yue-Yin Pan,

Xue-Ning Yang,

Yun Fan,

Zhe Liu,

Wen Fan,

g Yang,

Yan-Fang Guan,

Hao Sun,

WenZhao Zhong

Publication year - 2018

Publication title -

translational lung cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.474

H-Index - 41

eISSN - 2226-4477

pISSN - 2218-6751

DOI - 10.21037/tlcr.2018.04.15

Subject(s) - summit , medicine , lung cancer , blockade , immunotherapy , cancer , immune checkpoint , cancer immunotherapy , oncology , intensive care medicine , receptor , physical geography , geography

The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research